![Mark Fishman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark Fishman
Director/Board Member at
BEAM THERAPEUTICS INC.
Net worth: 560 041 $ as of 30/05/2026
Profile
Mark C.
Fishman is Lead Independent Director at Beam Therapeutics, Inc. since 2018.
Director at Aditum Bio Fund 1 LP since 2019.
Non-Executive Director at Versanis Bio, Inc. Director at Teres Bio, Inc. Director at Anteris Bio, Inc. Chief-Pathways Clinical Service at The General Hospital Corp.
Trustee-Emeritus at The Children's Hospital of Philadelphia.
Former Chairman of Novartis Institute for Functional Genomics, Inc. Chairman of Semma Therapeutics, Inc. from 2016 to 2019.
Director at Novartis International Pharmaceutical Ltd. Founding Director of Cardiovascular Research Center.
Director at Geneception, Inc. Member-Executive Board at Novartis AG.
Founding President of Novartis Institutes for Biomedical Research, Inc. from 2002 to 2016.
Trustee at The Marine Biological Laboratory.
Professor at Harvard Medical School.
Education includes undergraduate degree from Yale University in 1972 and doctorate from Harvard Medical School in 1976.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 02/06/2026 | 17,007 ( 0.02% ) | 560 041 $ | 30/05/2026 |
Mark Fishman active positions
| Companies | Position | Start |
|---|---|---|
| BEAM THERAPEUTICS INC. | Director/Board Member | 30/04/2018 |
The Children's Hospital of Philadelphia
 The Children's Hospital of Philadelphia Hospital/Nursing ManagementHealth Services Operates hospitals | Director/Board Member | - |
Anteris Bio, Inc.
 Anteris Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for the treatment of renal disease | Director/Board Member | - |
Versanis Bio, Inc.
 Versanis Bio, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Director/Board Member | - |
Aditum Bio Fund 1 LP
 Aditum Bio Fund 1 LP Investment ManagersFinance Functions as a venture capital fund | Director/Board Member | 31/01/2019 |
The General Hospital Corp.
 The General Hospital Corp. Hospital/Nursing ManagementHealth Services Functions as a non profit organization that operates general hospital | Corporate Officer/Principal | - |
Teres Bio, Inc.
 Teres Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage life sciences company which develops novel therapies for skin diseases | Director/Board Member | - |
Former positions of Mark Fishman
| Companies | Position | End |
|---|---|---|
Semma Therapeutics, Inc.
 Semma Therapeutics, Inc. BiotechnologyHealth Technology Develops transformative therapies for patients who currently depend on insulin injections | Chairman | 31/12/2018 |
| NOVARTIS AG | Corporate Officer/Principal | 29/02/2016 |
| ░░░░░░░░ ░░░░░░░░░░ ░░░ ░░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░ ░░░░░░ ░░░░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Training of Mark Fishman
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
86
1st degree connections
17
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 17 |
|---|---|
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
The General Hospital Corp.
The General Hospital Corp. Hospital/Nursing ManagementHealth Services Functions as a non profit organization that operates general hospital | Health Services |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Commercial Services |
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts research related to biotechnology and medicine | Commercial Services |
The Marine Biological Laboratory
 The Marine Biological Laboratory Miscellaneous Commercial ServicesCommercial Services Provides research and educational services | Commercial Services |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis International Pharmaceutical Ltd.
 Novartis International Pharmaceutical Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Health Technology |
The Children's Hospital of Philadelphia
The Children's Hospital of Philadelphia Hospital/Nursing ManagementHealth Services Operates hospitals | Health Services |
Semma Therapeutics, Inc.
Semma Therapeutics, Inc. BiotechnologyHealth Technology Develops transformative therapies for patients who currently depend on insulin injections | Health Technology |
Cardiovascular Research Center
 Cardiovascular Research Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Beam Therapeutics, Inc.
 Beam Therapeutics, Inc. BiotechnologyHealth Technology Operate as a biotechnology company that develops precision genetic medicines, gene editing and delivery technologies | Health Technology |
Aditum Bio Fund 1 LP
Aditum Bio Fund 1 LP Investment ManagersFinance Functions as a venture capital fund | Finance |
Geneception, Inc.
 Geneception, Inc. BiotechnologyHealth Technology Engages in research and development of biotechnology products | Health Technology |
Versanis Bio, Inc.
Versanis Bio, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Teres Bio, Inc.
Teres Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage life sciences company which develops novel therapies for skin diseases | Health Technology |
Anteris Bio, Inc.
Anteris Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for the treatment of renal disease | Health Technology |
- Stock Market
- Insiders
- Mark Fishman
